GT Biopharma announces departure of President of R&D and CMO Gregory Berk

GT Biopharma, Inc.

Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.
No successor or interim replacement named in the filing.
Departure comes as GT Biopharma (GTBP) advances its cancer immunotherapy pipeline.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gregory Berk

President of Research & Development and Chief Medical Officer

GTBP · GT Biopharma, Inc.

Effective: 2022-12-08
Filed: December 13, 2022, 6:59 PM ET

Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Berk departed as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..

Action: no longer employed
Role: President of Research & Development and Chief Medical Officer

Exact text from the filing

Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-035311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.